Has Danessa Vazquez Ramos received payments from drug or device companies?

Yes. Drug and device makers reported $3,271 in general payments to Danessa Vazquez Ramos across 118 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Danessa Vazquez Ramos did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Danessa Vazquez Ramos come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Danessa Vazquez Ramos

Pulmonary Disease · Mayaguez, PRNPI 1194051094

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.6% of the total across 118 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations.

$3,271in general payments, 2019–2025

Across 118 payments — averaging $27.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$567
GSK$509
United Therapeutics Corporation$393
Boehringer Ingelheim$384
Viatris Specialty LLC$239
Merck$214
plus $965 from 10 others

What the payments were for

Food & beverage$3,259100%
Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	21	$567
GSK	20	$509
United Therapeutics Corporation	10	$393
Boehringer Ingelheim	13	$384
Viatris Specialty LLC	9	$239
Merck	5	$214
Sanofi	9	$181
Mylan Specialty L.p.	7	$156
Takeda Pharmaceuticals U.S.A., Inc.	6	$154
Johnson & Johnson	5	$135
PBG Puerto Rico LLC	5	$109
Amgen	3	$66
ANI Pharmaceuticals, Inc.	2	$59
Olympus Latin America, Inc.	1	$48
Insmed, Inc.	1	$35
E.r. Squibb & Sons, L.L.C.	1	$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ANORO ELLIPTA$125
TYVASO$102

How this compares

$3,271 in reported general payments places this provider in the 60th percentile of 138 pulmonary disease providers in Puerto Rico.

See all pulmonary disease providers in Puerto Rico →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OfevNintedanib Esylate	110	$1,436,834
AdempasRiociguat	48	$666,085
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	262	$174,288
IngrezzaValbenazine Tosylate	12	$88,616
Spiriva RespimatTiotropium Bromide	99	$52,740
EliquisApixaban	52	$30,383
Breo ElliptaFluticasone/Vilanterol	57	$24,053
Albuterol Sulfate HfaAlbuterol Sulfate	538	$21,883
Fluticasone Propionate HfaFluticasone Propionate	73	$20,728
Wixela InhubFluticasone Propion/Salmeterol	150	$20,530
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr	37	$17,773
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate	60	$17,389
Incruse ElliptaUmeclidinium Bromide	42	$15,556
Arnuity ElliptaFluticasone Furoate	67	$15,491
Stiolto RespimatTiotropium Br/Olodaterol Hcl	28	$13,762

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat	$384	$1,503,336237 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta	$509	$247,161465 claims
AstraZenecaBreztri Aerosphere, Symbicort	$567	$11,91726 claims
Johnson & JohnsonXarelto	$135	$6,87112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 138 pulmonary disease providers in Puerto Rico.

Other pulmonary disease in Mayaguez

See the full list for Puerto Rico →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →